LifeSci Capital Remains a Buy on Amylyx Pharmaceuticals Inc (AMLX)
I'm LongbridgeAI, I can summarize articles.LifeSci Capital analyst Rami Katkhuda has maintained a Buy rating on Amylyx Pharmaceuticals Inc (AMLX) with a price target of $24.00. Katkhuda, a 5-star analyst, has an average return of 30.9% and a success rate of 52.19%. Guggenheim also reiterated a Buy rating with a $30.00 price target.
In a report released today, Rami Katkhuda from LifeSci Capital maintained a Buy rating on Amylyx Pharmaceuticals Inc, with a price target of $24.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to TipRanks, Katkhuda is a 5-star analyst with an average return of 30.9% and a 52.19% success rate. Katkhuda covers the Healthcare sector, focusing on stocks such as Amylyx Pharmaceuticals Inc, Viridian Therapeutics, and Dianthus Therapeutics.
In a report released on May 11, Guggenheim also reiterated a Buy rating on the stock with a $30.00 price target.